Arnorfa Biotech 2025 Q4 Financials
Key facts
- Arnorfa Biotech 2025 Q4 Financials
- Arnorfa Biotech (Company Code: 4133) reported an operating revenue of 351 million NTD and a net loss after tax of 1 million NTD for Q4 2025. The basic earnings per share were -0.02 NTD.
- Source: PR Times
- Date: December 1, 2025
Direct answer
Arnorfa Biotech (Company Code: 4133) reported an operating revenue of 351 million NTD and a net loss after tax of 1 million NTD for Q4 2025. The basic earnings per share were -0.02 NTD.
- Citation
- Arnorfa Biotech 2025 Q4 Financials (December 1, 2025), PR Times
- Source
- PR Times
- Date
- December 1, 2025
Arnorfa Biotech (Company Code: 4133) reported an operating revenue of 351 million NTD and a net loss after tax of 1 million NTD for Q4 2025. The basic earnings per share were -0.02 NTD.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Company Code: 4133 Company Name: Arnorfa Biotech Co., Ltd. Industry: Biotechnology and Medical Industry Year/Quarter: 2025 Q4 Basic Earnings Per Share: -0.02 NTD Operating Revenue: 351 million NTD Net Income After Tax: -1 million NTD
FAQ
What are the key facts in this article?
Arnorfa Biotech (Company Code: 4133) reported an operating revenue of 351 million NTD and a net loss after tax of 1 million NTD for Q4 2025. The basic earnings per share were -0.02 NTD.
What is the direct answer?
Arnorfa Biotech (Company Code: 4133) reported an operating revenue of 351 million NTD and a net loss after tax of 1 million NTD for Q4 2025. The basic earnings per share were -0.02 NTD.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-4133-2025Q4 | December 1, 2025